Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Medical research council working parties on leukaemia in adults and children. Acute myeloid leukaemia trial 15.

Next Previous
X
Search
Trial Profile

Medical research council working parties on leukaemia in adults and children. Acute myeloid leukaemia trial 15.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemtuzumab ozogamicin (Primary) ; Amsacrine; Antineoplastics; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Fludarabine; Idarubicin; Lestaurtinib; Mercaptopurine; Mitoxantrone; Tretinoin
  • Indications Acute myeloid leukaemia; Acute promyelocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MRC AML 15

    • Most Recent Events

    • 12 Aug 2013 Results published in the Journal of Clinical Oncology.
    • 13 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 08 Dec 2009 Results have been reported at the 51st Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top